Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.56 USD
+0.12 (8.33%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.55 -0.01 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Pacific Biosciences of California (PACB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.23 | $8.00 | $2.00 | 124.31% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Pacific Biosciences of California comes to $3.23. The forecasts range from a low of $2.00 to a high of $8.00. The average price target represents an increase of 124.31% from the last closing price of $1.44.
Analyst Price Targets (11)
Broker Rating
Pacific Biosciences of California currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, seven are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PACB.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 7 | 7 | 7 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.08 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | Piper Sandler | David M Westenberg | Hold | Hold |
8/8/2024 | Cantor Fitzgerald & Co | Ross Osborn | Strong Buy | Strong Buy |
8/8/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Hold | Hold |
8/1/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
4/18/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Hold |
4/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/17/2024 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Hold |
12/13/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 14 |
Average Target Price | $3.23 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.20 |